The latest developments across the GLP-1 landscape, from new drug approvals and clinical research to pricing changes and policy shifts. Stay informed on the updates that affect Ozempic, Wegovy, Mounjaro, and the wider category.
News & Updates
Foundayo is a newly approved oral GLP-1 medication that offers a pill-based alternative to injectable weight loss drugs like Wegovy and Ozempic. This guide covers how it works, who it is for, what it costs, and the key questions to ask your doctor before switching or starting treatment.
A woman on Ozempic developed a hardened mass in her stomach called a bezoar, and doctors dissolved it with 1.5 liters of Diet Coke. This unusual case highlights a real but underreported risk for GLP-1 users: slowed stomach emptying. Here's what patients should know.
Medicare's GLP-1 bridge program is pushing to expand access to semaglutide and tirzepatide for eligible beneficiaries. Here's what the program covers, who qualifies, and how to prepare if you're currently paying out of pocket for these medications.
The Centers for Medicare and Medicaid Services is piloting coverage for GLP-1 medications used to treat obesity. This article breaks down what the pilot actually involves, what critics are questioning, and what it could mean for your out-of-pocket costs and access to medications like Wegovy and Zepbound.
Researchers are developing implantable devices that could one day deliver GLP-1-like effects without weekly injections. Here's what the science shows so far, how this compares to current options like semaglutide and tirzepatide, and what patients should know before getting excited.
"Ozempic feet" is a colloquial term for foot-related changes some people experience while losing weight rapidly on GLP-1 medications like semaglutide. This guide explains what causes it, what symptoms to watch for, and practical steps you can take to protect your foot health during treatment.
Some people with bulimia and other eating disorders report that GLP-1 medications significantly reduced their urges to binge eat. But this emerging area comes with real risks, important caveats, and questions that researchers are still working to answer. Here is what patients and caregivers need to know right now.
A small implantable device that delivers GLP-1 medication continuously is moving through development as a potential solution for long-term weight maintenance. Here is what patients currently on injections or considering GLP-1 therapy need to know about this emerging technology and how it compares to existing options.
